American Gene Technologies® Launches New Spinoff Company “Addimmune™” to Focus Exclusively on Development of HIV Cure
Addimmune will build upon the success of American Gene Technologies Phase 1 HIV clinical trial, accelerating the clinical development with dedicated investment and singular focus on HIV. (Rockville, Maryland – June 9, 2023) American Gene Technologies (AGT™), a clinical-stage biotechnology company based in Rockville, Maryland, is launching a new company — Addimmune — to…
Read MoreAmerican Gene Technologies® CEO Jeff Galvin Wins Life Sciences Voice Top Industry Leaders Award
American Gene™ founder recognized as one of the field’s most dynamic leaders. Jeff Galvin, CEO and founder of American Gene Technologies®, a clinical-stage biotechnology company based in Rockville, Maryland, has been awarded the Life Sciences Voice Top Industry Leaders Award. The award recognizes the most dynamic leaders in the life sciences industry, who are making…
Read MoreAmerican Gene Technologies® Phase I HIV Gene Therapy Clinical Trial Data Published in Frontiers Journal Shows Success in Safety & Durability
American Gene™ Plans for Phase 2 Trial of AGT103-T American Gene Technologies®, a clinical-stage biotechnology company based in Rockville, Maryland, has recorded data that meets the primary and secondary endpoints of its AGT103-T Phase 1 trial. The Phase 1 trial demonstrated that AGT103-T — an autologous T cell product that has been modified with the…
Read MoreAmerican Gene Technologies® Chief Medical Officer Honored by UCSF Endowment for HIV Dermatology and LGBTQ Health Research
Dr. Marcus Conant Named in UCSF’s Commitment to Pave Way for Next Generation of HIV Researchers American Gene Technologies, a clinical-stage biotechnology company based in Rockville, Maryland, congratulates Dr. Marcus Conant and the University of California San Francisco (UCSF) Medical Center’s Department of Dermatology for establishing The Marcus Conant, MD, Endowment for HIV Dermatology and…
Read MoreAmerican Gene Technologies® Welcomes Barry H. Wells, M.D., as Head of Business Development
Dr. Wells’ promotion comes as the company’s HIV clinical trial progresses American Gene Technologies, a clinical-stage biotechnology company based in Rockville, Maryland, has promoted Barry H. Wells, M.D. as head of business development. Dr. Wells joined the company’s investor relations team in 2019. “I am excited to have Barry leading our investor relations and…
Read MoreAmerican Gene Technologies® HIV Cure Clinical Trial Enters Critical Phase: Withdrawing Participants from Antiretrovirals
Beginning the analytic treatment interruption is a pivotal step to potentially demonstrating a gene therapy cure for HIV. American Gene Technologies, a clinical-stage biotechnology company, has reached a turning point in its HIV cure clinical trial: it began withdrawing participants from their antiretroviral drugs earlier this month. This clinical protocol, technically known as analytic treatment…
Read MoreAmerican Gene Technologies® Appoints Dr. Jeff Boyle as Chief Science Officer
Dr. Boyle’s biotech and intellectual property expertise strengthen the team as the company proceeds to next phase of its HIV cure clinical trial American Gene Technologies, a clinical-stage biotechnology company, has appointed Jeff Boyle, PhD as chief science officer. Dr. Boyle comes to the post with deep biotechnology expertise which will help further accelerate the…
Read MoreAmerican Gene Technologies® Attracts Investment from Ride Wave Ventures
AGT™ welcomes additional support of its HIV Cure clinical trial and broad gene therapy development platform American Gene Technologies, a clinical-stage biotechnology company working to cure HIV, announced today that angel investor Ride Wave Ventures has made its first investment in the company. Ride Wave Ventures’ investment adds to the more than $50 million…
Read MoreAmerican Gene Technologies® Launches “The Cure Chronicles” Video Series
“The Cure Chronicles” presents thoughtful conversations with people living with HIV, advocates, medical experts, policymakers, and others working toward ending the HIV epidemic. American Gene Technologies, a clinical-stage biotechnology company working to cure HIV, has launched a video series showcasing compelling HIV community conversations: The Cure Chronicles, hosted by the company’s CEO Jeff Galvin. …
Read MoreAmerican Gene Technologies® Applauds the State of Maryland for Supporting Biotech Investment
Maryland’s Biotechnology Investment Incentive Tax Credit (BIITC) program generates multiple benefits for the state American Gene Technologies, a clinical-stage biotechnology company working to cure HIV, thanks the State of Maryland for its commitment to supporting biotech research through initiatives like the Biotechnology Investment Incentive Tax Credit (BIITC) program. While AGT™ is no longer eligible for…
Read MoreAmerican Gene Technologies® Advances Closer to Demonstrating a Potential Cure for HIV
HIV cure clinical trial data shows safety and efficacy of AGT™ gene therapy treatment, the company will begin withdrawing participants from antiretrovirals in Q2 to test potential functional cure American Gene Technologies (AGT), a clinical-stage biotechnology company working to cure HIV, announced that the independent Institutional Review Board (IRB) overseeing its clinical trial approved the…
Read MoreAmerican Gene Technologies® HIV Clinical Trial Shows Blood Markers of Efficacy in Two More Patients
Data from a Total of Five Patients Demonstrates Critical Markers of the Company’s HIV Cure Gene & Cell Therapy American Gene Technologies, a clinical-stage biotechnology company working to cure HIV, announced that it has reached another important milestone for its HIV cure program. Five participants were treated with AGT103-T and are stably engrafted with genetically modified…
Read More